Dollar/Yen Jumps to 160.245, Last at 159.30
Dollar/Yen Surges, up 0.9% to 159.735
China's Yuan Opens Trade at 7.2400 per Dollar Vs Last Close at 7.2465
SK Innovation: Expects to See Increasing EV Battery Shipment in H2 Backed by Launches of New Evs in US
SK Innovation: Maintains Its Target to Reach Break Even Point for Its Battery Unit SK on in Second Half of This Year
Shanghai Composite Index to Open Down 0.1 Pct at 3,086.68 Points
China's CSI300 Index to Open Flat at 3,584.54 Points
China C.bank Injects 2 Bln Yuan via 7-Day Reverse Repos at 1.80% Vs Prior 1.80% - Statement
Hk’s Hang Seng Index to Open up 0.5% at 17,737.93 Points
SK Innovation: Has Secured Contingency Plans in Case of Block of the Strait of Hormuz
PBOC Sets Yuan Mid-Point at 7.1066 / Dlr Vs Last Close 7.2465
Brent Crude Futures Fall $1 to $88.50/Bbl
Ellison Is Offering to Buy a Block of Paramount Shares at a Premium to Their Current Price to Help Shore up the Company’s Finances- Bloomberg News
Tapaco Pcl - Appointed Baker & Mckenzie Sweden as Legal Advisor to Handle Bankruptcy Process of C4Hus AB
Tapaco Pcl - Entering Into Bankruptcy Process of Subsidiary C4Hus AB
SK Innovation: Plans to Carry Out Maintenance for Its No.4 Cud in Q2
China PBOC Expected to Set Yuan Mid-Point at 7.2579 per Dollar - Reuters Estimate
Dollar/Yen Down 0.15% at 158.115 in Early Deals, off Friday's 34-Yr Peak Around 158.44
SK Innovation: Demand Is Expected to Stay Firm Due to Strong Real Economy and Anticipation for Improved Demand in Emerging Market
SK Innovation: SK Innovation Expects Solid Refining Margins Projected to Continue in Q2
SK Innovation : Q1 Net Loss 98 Bln Won (Lseg Smartestimate 140 Bln Won)
SK Innovation: Q1 Operating Profit 625 Bln Won (Lseg Smartestimate 466 Bln Won)
SK Innovation: Q1 Revenue 18.9 Trln Won (Lseg Smartestimate 18 Trln Won)
Celltrion USA Signs Agreement With Express Scripts for Its Therapy for Autoimmune Diseases Including the First FDA-Approved Subcutaneous Infliximab Zymfentra™
Phibro Animal Health Corp - Acquisition Expected to Be Funded With Debt, and Co Received Financing Commitments From Number of Key Relationship Banks.
Phibro Animal Health Corp - Portfolio Is Expected to Boost Co's Profitability and Ebitda Margin and Be Accretive to Its Adjusted Earnings per Share
Phibro Animal Health Corp - Will Acquire Zoetis' MFA Product Portfolio, Certain Water Soluble Products and Related Assets
Phibro Animal Health Corp - Also Included in Agreement Are Six Manufacturing Sites, Four in U.S., One in Italy and One in China
Phibro Animal Health Corp - More Than 300 Zoetis Colleagues Supporting Manufacturing, Distribution, Commercial Activities to Transition to Pahc
Phibro Animal Health Corp - Definitive Agreement for $350 Mln